Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Edaxeterkib · KO-947

Small molecule · Inhibitor of extracellular signal-regulated kinase 1 (ERK1) (MAPK3) and extracellular signal-regulated kinase 2 (ERK2) (MAPK1) · developed by Kura Oncology

Phase 1 Most advanced trial (none active)
KURA Developer
1 Registered trials

What is Edaxeterkib?

Edaxeterkib (KO-947) is an intravenously administered small-molecule inhibitor that binds and inhibits ERK1 and ERK2, blocking MAPK/ERK-mediated signal transduction. It is being studied in advanced malignant neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KO-947
Drug type
Small molecule
Targets
extracellular signal-regulated kinase 1 (ERK1) (MAPK3), extracellular signal-regulated kinase 2 (ERK2) (MAPK1)
Mechanism
Inhibitor of extracellular signal-regulated kinase 1 (ERK1) (MAPK3) and extracellular signal-regulated kinase 2 (ERK2) (MAPK1)
Pathways
MAPK/ERK signal transduction, tumor cell proliferation and survival
Therapy area
Oncology
Developer
Kura Oncology, Inc. (KURA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
D9F5G5D3GN

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03051035 Phase 1 Advanced Malignant Neoplasm Terminated KURA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Malignant Neoplasm

Other drugs acting on MAPK3 / MAPK1

More from Kura Oncology

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KURA page.

Follow KURA, the company behind Edaxeterkib

See KURA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KURA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.